Collecting real-world data on trastuzumab-deruxtecan for advanced gastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather real-world data on patients with advanced gastric cancer who have started treatment with trastuzumab-deruxtecan (Enhertu) since September 2022. It will collect clinical data from patients currently undergoing treatment, those who have experienced disease progression, and those who have passed away or are in hospice care. The study will evaluate efficacy through metrics such as overall survival, progression-free survival, and tumor response rate, with data collection continuing until March 2027 for consenting patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged 19 years or older.
* Patients with pathologically confirmed metastatic, recurrent, or unresectable gastric/gastroesophageal adenocarcinoma.
* Patients whose tumor tissue shows HER2 immunohistochemistry (IHC) results of 3+ or 2+ with in-situ hybridization (ISH) positivity.
* Patients who received Trastuzumab Deruxtecan as third-line or later treatment.

Exclusion Criteria:

* Patients with HER2-negative gastric cancer.
* Patients who did not provide consent to participate in the study.
* Patients who received Trastuzumab Deruxtecan as first-line or second-line treatment as part of a clinical trial.

Where it's running

• minkyu Jung
  Seoul, Seoul, South Korea Recruiting

Study contacts

• Principal investigator: minkyu Jung — Yonsei Cencer center
• Study coordinator: minkyu Jung
• Email: minkjung@yuhs.ac
• Phone: 0222278406

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Predicting Immunotherapy Response in Advanced Gastric Cancer using PET Imaging

  This study tests whether FAPI PET/CT and Grazytracer PET/CT can predict how advanced gastric cancer will respond to preoperative immunotherapy-based treatment.

  Recruiting Ruijin Hospital · Shanghai · NCT07824479

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Trastuzumab Rezetecan and Gemcitabine before surgery for HER2-positive UTUC

  This study tests whether giving trastuzumab deruxtecan with gemcitabine before and around surgery can improve outcomes for people with HER2-positive upper tract urothelial cancer.

  Recruiting at 10 sites Phase 2 Tongji Hospital · Huanggang, Hubei and 9 other locations · NCT07741448

• Foslorapitant with Palonosetron to Help Prevent Nausea and Vomiting from Trastuzumab Rezetecan

  A single-arm study tests whether giving foslorapitant plus palonosetron can prevent chemotherapy-induced nausea and vomiting in adults receiving Trastuzumab Rezetecan.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07726433

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.